Safety of Everolimus and Pemetrexed in Lung Cancer Patients

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety of everolimus in combination with pemetrexed when used as treatment in patients with non small cell lung cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Everolimus; Pemetrexed; Sirolimus

Criteria

Inclusion criteria:

• Lung cancer

• Only one prior regimen of chemotherapy for the treatment of non small cell lung cancer

• Adequate bone marrow function

• Adequate liver function

• Adequate renal function

• Negative serum pregnancy test

Exclusion criteria:

• History of another primary malignancy in the last 5 years

• Having recently received an investigational drug

• Having recently received major surgery of wide field radiotherapy

• Chronic treatment with immunosuppressive therapy, steroids or liver enzyme modulators

• Severe or uncontrolled medical conditions

Other protocol-defined inclusion/exclusion criteria may apply